Skip to main content
Pay Bill Portals

How MRD Testing Helps Monitor Ovarian Cancer Recurrence

Published Date

September marks Ovarian Cancer Awareness Month—a time to honor survivors, raise awareness, and spotlight innovations that are changing the way we monitor recurrence. For many women, remission is not the end of the journey. Up to 80% of advanced ovarian cancers recur, often silently and without symptoms until the disease has progressed.

  • What is MRD?
    Minimal Residual Disease (MRD) refers to microscopic cancer cells that remain in the body after treatment—often undetectable by scans.

  • Why MRD Testing Matters:
    Tools like Signatera™ detect cancer DNA in the blood, offering an average 10-month lead time over imaging. This allows for earlier intervention and more personalized care.

  • Clinical Impact:
    Studies show MRD-positive patients have significantly shorter progression-free survival than MRD-negative patients. Monitoring MRD can guide treatment decisions and provide peace of mind.

MRD testing is redefining remission as an opportunity for proactive surveillance. This September, let’s empower patients with the tools to stay ahead of recurrence. Talk to your doctor about Signatera™ MRD testing and learn more about staying a step ahead in the fight against cancer.